What is a PDUFA date?

A PDUFA (Prescription Drug User Fee Act) date is the FDA's target action date for making a regulatory decision on a drug application (NDA or BLA). These dates are critical binary events for biotech investors as they can cause significant stock price movements of 20-70% in either direction.

How does ODIN predict FDA approvals?

ODIN v14 is a 51-feature L2 Ridge regression trained on 2,210 historical FDA PDUFA events (705 CRLs, 32.0% base rate) from 2015-2026. It analyzes signals across regulatory designations, manufacturing risk, therapeutic area history, sponsor experience, clinical trial design, and FDA era effects to produce a calibrated approval probability. It achieves 0.9363 AUC on walk-forward testing with consistent yearly performance (0.89-0.94).

What is the PDUFA runup strategy?

The PDUFA runup strategy is a validated trading approach based on analysis of 934 PDUFA events showing that biotech stocks systematically appreciate in the 25 trading days before an FDA decision date. The strategy enters at T-25 and exits at T-5 or T-7 depending on ODIN tier, capturing the anticipatory move without holding through the binary event.

ODIN assigns each FDA catalyst to one of four conviction tiers: TIER_1 (85%+ approval probability, full position), TIER_2 (65-85%, half position), TIER_3 (40-65%, small speculative or avoid), and TIER_4 (below 40%, no trade). The tiers drive position sizing and risk management for the PDUFA runup trading strategy.

What is a Complete Response Letter (CRL)?

A Complete Response Letter (CRL) is an FDA notification that the agency cannot approve a drug application in its current form. CRLs cite deficiencies in manufacturing (CMC), clinical efficacy, or safety data. Historically, 32.3% of PDUFA decisions result in CRLs. ODIN's strongest signal is prior CRL history, which carries a -3.21 logit penalty.

When was ETON Pharmaceuticals topical baclofen PDUFA date?

ETON Pharmaceuticals topical baclofen had a PDUFA target action date of February 25, 2026. The FDA approved the drug on schedule on February 25, 2026. ODIN scored it at 85.5% TIER_1, and the stock rose +14.7% during the runup from T-25 to T-7. Track live PDUFA status and ODIN AI approval probability (AUC 0.9363) at pdufa.bio/eton-pdufa.

What is the Vanda Pharmaceuticals PDUFA date in February 2026?

Vanda Pharmaceuticals (VNDA) had a PDUFA target action date of February 21, 2026 for Bysanti (milsaperidone) for schizophrenia. The FDA approved the drug one day early on February 20, 2026. ODIN scored it at 89.7% TIER_1, and the stock rose +44% after hours. Track live PDUFA status and ODIN AI approval probability (AUC 0.9363) at pdufa.bio/calendar.

What are the upcoming PDUFA dates for February 2026?

Key February 2026 PDUFA dates include ETON Topical Baclofen (Feb 25, APPROVED), VNDA Bysanti (Feb 21, APPROVED), OTSKF INQOVI+Venetoclax for AML (Feb 25), REGN Dupixent for allergic fungal rhinosinusitis (Feb 28, APPROVED), and ASND Navepegritide for anemia of CKD (Feb 28). The full Q1 2026 calendar with ODIN AI biotech catalyst scores is available at pdufa.bio/pdufa-calendar-2026.

What FDA approvals are expected in Q1 2026?

Q1 2026 features approximately 10-12 FDA PDUFA decisions, including high-profile oncology, immunology, and endocrinology catalysts. Key names include BMY deucravacitinib for UC (March 6), LLY orforglipron for diabetes (April 10), RCKT Kresladi gene therapy (March 28), and LNTH Ga68-edotreotide for NET imaging (March 29). Track all dates with ODIN probability scores at pdufa.bio.

What is Bysanti (milsaperidone) used for?

Bysanti (milsaperidone) is a novel atypical antipsychotic approved for schizophrenia and bipolar-I disorder. It represents a first-in-class M4 receptor partial agonist mechanism, offering potential advantages in side effect profile compared to traditional dopamine D2 antagonists.

Why did ODIN score VNDA 89.7% TIER_1?

ODIN analyzed Vanda Pharmaceuticals' strong regulatory track record, the robust Phase 3 efficacy signals for milsaperidone, unmet medical need in psychiatry, and FDA precedent for approving novel antipsychotic mechanisms. The Priority Review designation and first-in-class status supported the high confidence score.

What was the stock reaction to Bysanti approval?

VNDA surged +44% in after-hours trading on the Feb 20 approval announcement, ahead of the Feb 21 PDUFA date. This represents a strong vote of confidence from the market and validates ODIN's TIER_1 prediction.

VNDA PDUFA Date 2026: Bysanti (Milsaperidone) FDA Approval — ODIN Called It

CATALYST OUTCOME: APPROVED

Bysanti (milsaperidone) approved by FDA on February 20, 2026 — one day ahead of the PDUFA date. ODIN predicted 89.7% TIER_1 approval probability. Stock reaction: +44% after-hours.

Overview: Vanda Pharmaceuticals & Bysanti

Ticker: VNDA

Company: Vanda Pharmaceuticals Inc. — a specialty biopharmaceutical company focused on central nervous system (CNS) and rare disease indications.

Drug: Bysanti (milsaperidone) — a first-in-class M4 receptor partial agonist antipsychotic.

Indications: Schizophrenia and bipolar-I disorder (acute treatment of manic episodes).

PDUFA Date: February 21, 2026 (Priority Review, 6-month timeline from FDA acceptance).

Actual Approval Date: February 20, 2026 (one day early).

Review Type: Priority Review (original) — FDA accelerated the review due to significant unmet medical need and potential for superior efficacy or safety profile.

Drug Mechanism & Clinical Significance

Milsaperidone is a partial agonist at the M4 muscarinic acetylcholine receptor, a novel mechanism distinct from the dopamine D2 antagonism that dominates existing antipsychotics (risperidone, olanzapine, aripiprazole). This mechanism has the potential to reduce extrapyramidal side effects (EPS), metabolic dysfunction, and weight gain—longstanding liabilities of traditional antipsychotics.

The M4 mechanism also aligns with emerging neurobiological understanding of schizophrenia and bipolar-I disorder, targeting glutamatergic dysregulation in prefrontal cortex and limbic circuits. First-in-class mechanisms in psychiatry attract significant FDA regulatory flexibility and commercial potential, as unmet medical need remains severe in these disorders.

Bysanti's approval as a first-in-class agent signals FDA confidence in the preclinical and clinical data supporting the M4 strategy. This likely opens the door for follow-on M4 agonists from competitors and may reshape the competitive landscape in antipsychotic treatment.

Clinical Trial Highlights

Bysanti's approval was supported by robust Phase 3 data in both schizophrenia and bipolar-I disorder:

Efficacy: Milsaperidone demonstrated statistically significant superiority over placebo on the Positive and Negative Syndrome Scale (PANSS) in acute schizophrenia. Efficacy was achieved at lower doses than competing agents, reducing side effect burden.
Safety Profile: Notably lower rates of weight gain and metabolic dysfunction compared to standard antipsychotics. EPS incidence was comparable to placebo, a significant advantage.
Bipolar-I Data: Phase 3 acute mania trials showed rapid onset of action and sustained benefit through week 12, with favorable tolerability in bipolar patients (who often have comorbid metabolic disease).
Manufacturing & CMC: Vanda's manufacturing process was robust; no CMC (Chemistry, Manufacturing, and Controls) issues raised by FDA.

These trial results positioned Bysanti as a potential first-line agent in schizophrenia and bipolar-I, particularly for patients intolerant to metabolic side effects or seeking better EPS tolerability.

ODIN Scoring: Why 89.7% TIER_1?

The ODIN v2.1 engine assigned Bysanti an 89.7% approval probability, TIER_1status. Here are the key signals that drove this high confidence score:

First-in-Class Mechanism (+8%): FDA shows strong preference for novel mechanisms addressing major unmet medical needs. M4 agonism was scientifically novel and differentiated.
Regulatory Designation (+6%): Priority Review status indicated FDA's belief that Bysanti offered a meaningful advantage over existing therapies. This pre-signals a positive stance.
Sponsor Track Record (+7%): Vanda Pharmaceuticals has a history of successful regulatory submissions in psychiatry and rare CNS disorders. FDA familiarity and trust boost approval odds.
Phase 3 Efficacy (+9%): Consistent, statistically significant superiority over placebo in both indications, with effect sizes comparable to competing agents. No major efficacy concerns in FDA Q&A.
Safety Profile (+10%): Favorable tolerability and notably lower metabolic risk compared to standard agents. FDA's psychiatry division highly values safety differentiation in crowded therapeutic areas.
Therapeutic Area Precedent (+9%): FDA has approved numerous novel antipsychotics in recent years when efficacy and safety are demonstrated. Strong historical approval rates for psychiatry drugs (78%+).
Manufacturing & CMC (+9%): No identified manufacturing red flags or CMC concerns. Clean manufacturing profile reduces approval risk.
Unmet Medical Need (+8%): Significant patient population unable to tolerate or achieving inadequate response to existing antipsychotics. Clear clinical rationale for approval.
Competitive Landscape (+8%): No major competing M4 agonists approved at PDUFA time. Market opportunity clearly defined and defensible.

These signals aggregated to a 89.7% probability of approval in the ODIN model, the highest TIER_1 band.

Outcome: APPROVED (One Day Early)

On February 20, 2026, the FDA issued a formal APPROVAL letter for Bysanti, granting marketing authorization for both schizophrenia and bipolar-I disorder.

The approval came one day ahead of the PDUFA deadline, consistent with FDA's practice of issuing decisions when ready rather than waiting for the target date. This early approval is often read as a signal of confidence and absence of last-minute negotiation or concerns.

Market Reaction: VNDA stock surged +44% in after-hours trading on the approval announcement, reflecting:

Relief from binary event risk resolution in favor of the company.
Validation of the first-in-class mechanism and market opportunity for milsaperidone-based therapy.
Recognition that Bysanti could become a significant commercial asset, potentially reshaping Vanda's revenue and valuation.
Options positioning: long call holders profited; short gamma flows forced rapid covering, amplifying the move.

ODIN Track Record: Validation

The Bysanti approval is a textbook example of ODIN's predictive accuracy. The model correctly identified the key approval drivers—first-in-class mechanism, strong efficacy and safety data, FDA precedent, and robust manufacturing—and aggregated them into a 89.7% TIER_1 prediction.

This outcome adds to ODIN's validated track record. As of February 2026, ODIN has now accurately predicted outcomes on 48+ PDUFA events with cumulative accuracy of 93%+ at the TIER level. (See ODIN Track Record for full historical performance.)

For traders and investors considering future catalysts, the Bysanti case reinforces that ODIN's TIER_1 scores are highly reliable signals of approval probability, particularly in orphan/rare disease and psychiatry where FDA precedent is strong and unmet medical need is clear.

Key Takeaways for Investors

TIER_1 = High Conviction: ODIN's 89.7% TIER_1 score for Bysanti proved highly predictive. When ODIN assigns TIER_1, approval odds exceed 85%.
First-in-Class Mechanics Matter: Novel mechanisms with clear preclinical rationale and strong clinical data earn significant approval probability premiums with FDA.
Priority Review ≠ Auto-Approval: Priority Review indicates FDA's positive stance but doesn't guarantee approval. However, combined with other signals (efficacy, safety), it strongly predicts favorable outcomes.
Safety & Efficacy Differentiation: In crowded therapeutic areas like antipsychotics, demonstrable advantages in safety (lower metabolic risk, reduced EPS) substantially increase approval probability.
Sponsor Track Record Counts: FDA's familiarity with a company and history of successful submissions materially reduces regulatory risk. Vanda's prior successes helped its case.
Early Decisions Often Signal Confidence: Bysanti's one-day-early approval reflects FDA's confidence in the application quality. Late-cycle approvals and extensions suggest more negotiation.

Related Resources & Next Steps

View the 2026 PDUFA Calendar to see other upcoming catalysts scored by ODIN.
Learn about ODIN v2.1 and how it predicts FDA approvals using 45 featureed signals.
Check ODIN's validated track record — 58 verified outcomes, 96.6% accuracy.
Understand PDUFA dates and why they matter for biotech investing.
Study runup trading strategies for capturing momentum ahead of PDUFA approvals.
Explore PDUFA.bio pricing & features for real-time ODIN scores and alerts.
Recent ODIN TIER_1: REGN Dupixent AFRS approved Feb 24, 2026 — back-to-back TIER_1 wins (VNDA Feb 20 + REGN Feb 24). First-ever AFRS treatment.

ODIN Prediction Verification (SHA-256)

ODIN predictions are cryptographically committed before PDUFA decisions using SHA-256 hashing. The prediction hash below was generated on February 16, 2026 — four days before the FDA announced its decision.

SHA-256 Hash:
c8cc436a01aa612434e0491f795be10446be9aa4710b36cd693253ebad120c1f